Dihydropyridomycins as New Antitubercular Agents: Synthesis and SAR Studies

Pyridomycin (1) is a bacterial natural product that was first isolated in 1953 by Maeda and coworkers from the Streptomyces strain 6706.[1] The compound was shown to exhibit significant in vitro anti-tubercular activity (MIC = 0.3 μg/mL, H37Rv) and low cytotoxicity in mice.[1,2] The molecular target of 1 has recently been identified as the NADH-dependent enoyl-ACP reductase InhA, which is also the target of the clinically used anti-TB drug isoniazid.[2]